Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 3
2019 2
2020 3
2021 3
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
When the MET receptor kicks in to resist targeted therapies.
Fernandes M, Jamme P, Cortot AB, Kherrouche Z, Tulasne D. Fernandes M, et al. Among authors: jamme p. Oncogene. 2021 Jun;40(24):4061-4078. doi: 10.1038/s41388-021-01835-0. Epub 2021 May 24. Oncogene. 2021. PMID: 34031544 Review.
The multiple paths towards MET receptor addiction in cancer.
Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin MC, Tulasne D. Duplaquet L, et al. Among authors: jamme p. Oncogene. 2018 Jun;37(24):3200-3215. doi: 10.1038/s41388-018-0185-4. Epub 2018 Mar 19. Oncogene. 2018. PMID: 29551767 Review.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L. Véron M, et al. Among authors: jamme p. Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. Eur J Cancer. 2022. PMID: 36335780 Clinical Trial.
Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgräber U, Stallmach A, Steighardt J, Zipprich A; Liver-HERO Study Group. Ripoll C, et al. Trials. 2023 Apr 5;24(1):258. doi: 10.1186/s13063-023-07261-9. Trials. 2023. PMID: 37020315 Free PMC article. Clinical Trial.
Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.
Oberlé M, Jamme P, Mansard S, Machet L, Hervieu A, Kramkimel N, Greliak A, Jarrousse AS, Derangère V, Dudoignon D, Descarpentries C, Mortier L. Oberlé M, et al. Among authors: jamme p. JCO Precis Oncol. 2022 Mar;6:e2100417. doi: 10.1200/PO.21.00417. JCO Precis Oncol. 2022. PMID: 35319964 No abstract available.
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Fernandes M, Hoggard B, Jamme P, Paget S, Truong MJ, Grégoire V, Vinchent A, Descarpentries C, Morabito A, Stanislovas J, Farage E, Meneboo JP, Sebda S, Bouchekioua-Bouzaghou K, Nollet M, Humez S, Perera T, Fromme P, Grumolato L, Figeac M, Copin MC, Tulasne D, Cortot AB, Kermorgant S, Kherrouche Z. Fernandes M, et al. Among authors: jamme p. Mol Oncol. 2023 Nov;17(11):2257-2274. doi: 10.1002/1878-0261.13397. Epub 2023 Jul 14. Mol Oncol. 2023. PMID: 36799689 Free PMC article.
23 results